Abstract:Background: Sunitinib, a newly developed multi-targeted tyrosine kinase inhibitor (TKI), has become a common therapeutic option for managing advanced renal cell carcinoma (RCC). Examining the mechanism underlying the interaction between sunitinib and isavuconazole was the aim of this effort. Methods: The concentrations of sunitinib and its primary metabolite, N-desethyl sunitinib, were analyzed and quantified using ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS). Our study evaluated the potential interaction between isavuconazole and sunitinib using rat liver microsomes (RLM), human liver microsomes (HLM), and in vivo rat models. For the in vivo study, two groups (n = 5) of Sprague-Dawley (SD) rats were randomly allocated to receive sunitinib either with or without co-administration of isavuconazole. Additionally, the effects of isavuconazole on the metabolic stability of sunitinib and N-desethyl sunitinib were studied in RLM in vitro. Results: Our findings demonstrated that in RLM, isavuconazole exhibited a mixed non-competitive and competitive inhibition mechanism, with an IC50 (half maximal inhibitory concentration) value of 1.33 µM. Meanwhile, in HLM, isavuconazole demonstrated a competitive inhibition mechanism, with an IC50 of 5.30 µM. In vivo studies showed that the presence of isavuconazole significantly increased the pharmacokinetic characteristics of sunitinib, with the AUC(0→t), AUC(0→∞), and Tmax rising to approximately 211.38%, 203.92%, and 288.89%, respectively, in contrast to the control group (5 mg/kg sunitinib alone). The pharmacokinetic characteristics of the metabolite N-desethyl sunitinib in the presence of isavuconazole remained largely unchanged compared to the control group. Furthermore, in vitro metabolic stability experiments revealed that isavuconazole inhibited the metabolic processing of both sunitinib and N-desethyl sunitinib. Conclusions: Isavuconazole had a major impact on sunitinib metabolism, providing fundamental information for the precise therapeutic administration of sunitinib.

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial

Corrigendum: Effect of Itraconazole on the Safety and Pharmacokinetics of Antitumor SHR6390

Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers

Differential Effects of Ketoconazole, Fluconazole, and Itraconazole on the Pharmacokinetics of Pyrotinib in Vitro and in Vivo

Effect of CYP3A4 Induction and Inhibition on the Pharmacokinetics of SHR0302 in Healthy Subjects.

Effect of SHR0302 on the Pharmacokinetics of CYP3A4, CYP2C8, CYP2C9, and CYP2C19 Probe Substrates in Healthy Volunteers: A Cocktail Analysis

The effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of the first-in-class ACKR3/CXCR7 antagonist, ACT-1004-1239

Evaluation of drug–drug interactions of a novel potent FLT3 inhibitor SKLB1028 in healthy subjects

Effect of itraconazole on pharmacokinetics of viaminate in healthy subjects

Effect of itraconazole on the pharmacokinetics of all-trans-retinoic acid in rabbits

Drug-drug Interaction Potential of SH-1028, a Third-Generation EGFR-TKI: in Vitro and Clinical Trials

Pharmacokinetic Interaction of Chiglitazar with CYP3A4 Inducer or Inhibitor: an Open-Label, Sequential Crossover, Self-Control, 3-Period Study in Healthy Chinese Volunteers

Study on pharmacokinetics and bioequivalence of itraconazole dispersible tablets in healthy volunteers

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treatment of invasive fungal infection in China

Phase 1 Study to Evaluate the Effects of Rifampin or Itraconazole on the Pharmacokinetics of Limertinib (ASK120067), a Novel Mutant-Selective Inhibitor of the Epidermal Growth Factor Receptor in Healthy Chinese Subjects.

In vitro activities of the tetrazole SHR8008 compared to itraconazole and fluconazole against Candida and Cryptococcus species

The Pharmacokinetic Interaction of Tirabrutinib with Voriconazole, Itraconazole, and Fluconazole in SD Rats by UPLC-MS/MS

Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.

The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial

Effect of isavuconazole on the pharmacokinetics of sunitinib and its mechanism

Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers